Landos Biopharma, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Compensation expense related to vesting of common stock issued to Xontogeny
Depreciation
Stock-based compensation expense
Amortization of premium on marketable securities
Non-cash loss on termination of lease
Gain on sale of equipment
Loss from foreign exchange
Changes in operating assets and liabilities:
Prepaid expenses and other assets
Accounts payable
Other liabilities
Net cash used in operating activities
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment
Proceeds from sale of property and equipment
Purchases of available-for-sale marketable securities
Proceeds from sales and maturities of marketable securities
Net cash provided by (used in) investing activities
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of pre-funded warrants for the purchase of common stock, net of issuance costs
Financing costs paid
Proceeds from exercise of stock options
Repurchase and retirement of common stock
Net cash provided by financing activities
Net change in cash and cash equivalents
Net change in cash, cash equivalents and restricted cash
Cash and cash equivalents at beginning of period
Effect of exchange rates on cash
Cash and cash equivalents at end of period
Supplemental non-cash disclosure: NONCASH INVESTING AND FINANCING ACTIVITY:
Non-cash gain on sale of fixed assets
Purchase of fixed assets in accounts payable
Deferred offering costs included in accounts payable and accrued liabilities
Conversion of Series A and B convertible preferred stock to common stock
Operating right-of-use asset obtained in exchange for operating lease liability
Derecognition of operating right-of-use asset and operating lease liability upon termination of lease
Unrealized loss on available-for-sale marketable securities
Non-cash deferred financing costs

Comments